2-methyl-5-piperidin-4-ylquinoline | 698982-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-methyl-5-piperidin-4-ylquinoline
• 英文别名: 2-methyl-5-(4-piperidinyl)quinoline
• CAS: 698982-69-3
• 化学式: C₁₅H₁₈N₂
• 分子量: 226.321
• InChiKey: LRJUSAZJVCXDGD-UHFFFAOYSA-N

物化性质

• 沸点：
  379.5±42.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-5-piperidin-4-ylquinoline 、 ethyl 6-(2-oxoethyl)imidazo[1,5-a]quinoline-3-carboxylate 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 6.5h， 以52%的产率得到ethyl 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperidinyl]ethyl}imidazo[1,5-a]quinoline-3-carboxylate
  参考文献：
  名称：

  [EN] FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS
  [FR] DERIVES TRICYCLIQUES ACCOLES POUR LE TRAITEMENT DE TROUBLES PSYCHOTIQUES

  摘要：

  式中R1、R2、X、A、Y、B、Z1、Q、p、r和s在说明书中定义的用于治疗精神疾病、抑郁障碍、焦虑障碍和性功能障碍的(I)式化合物。

  公开号：

  WO2006024517A1

文献信息

• 5-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones: Dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3
  作者：Steven M. Bromidge、Roberto Arban、Barbara Bertani、Manuela Borriello、Anna-Maria Capelli、Romano Di-Fabio、Stefania Faedo、Massimo Gianotti、Laurie J. Gordon、Enrica Granci、Alessandra Pasquarello、Simone K. Spada、Angela Worby、Laura Zonzini、Valeria Zucchelli

  DOI：10.1016/j.bmcl.2010.09.085

  日期：2010.12

  5-2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones have been identified with different combinations of 5-HT1 autoreceptor antagonist and hSerT potencies and excellent rat PK profiles. The availability of tool compounds with a range of profiles at targets known to play a key role in the control of synaptic 5-HT levels will allow exploration of

  5- 2- [4-（2-甲基-5-喹啉基）-1-哌嗪基]乙基} -2（1 H）-喹啉酮和3,4-二氢-2（1 H）-喹啉酮已被鉴定为5-HT 1自体受体拮抗剂和hSerT效力的不同组合以及出色的大鼠PK谱。在已知在控制突触5-HT水平中起关键作用的靶标上具有一系列分布图的工具化合物的可用性将允许在一系列动物行为和疾病模型中探索不同的药理分布图。
• [EN] BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS<br/>[FR] DERIVES DE BENZOXAZINONE, PREPARATION DE CEUX-CI ET UTILISATIONS DE CEUX-CI DANS LE TRAITEMENT DE TROUBLES DU SNC ET D'AUTRES TROUBLES
  申请人：GLAXO GROUP LTD

  公开号：WO2004046124A1

  公开（公告）日：2004-06-03

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed:wherein A, R1, R2, R3, p, q, A and X are as defined in the specification. Preparation of the compounds and uses in the treatment of CNS and other disorders, including depression and anxiety, are also disclosed.

  公开了化合物的公式(I)及其药用盐：其中A、R1、R2、R3、p、q、A和X的定义如规范中所述。还公开了化合物的制备方法以及在治疗中枢神经系统和其他疾病，包括抑郁症和焦虑症中的用途。
• Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
  申请人：Bertani Barbara

  公开号：US20060264429A1

  公开（公告）日：2006-11-23

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein A, R1, R2, R3, p, q, A and X are as defined in the specification. Preparation of the compounds and uses in the treatment of CNS and other disorders, including depression and anxiety, are also disclosed.

  公开了化学式（I）的化合物及其药学上可接受的盐：其中A、R1、R2、R3、p、q、A和X的定义如规范中所述。还公开了这些化合物的制备方法以及在治疗中枢神经系统和其他疾病，包括抑郁和焦虑症方面的用途。
• 5-QUINOLINONE DERIVATIVES AS 5HT1A RECEPTOR MODULATORS FOR TREATING SEXUAL DYSFUNCTION, COGNITION IMPAIRMENT, PSYCHOTIC DISORDERS, ANXIETY, DEPRESSION, ETC.
  申请人：Bertani Barbara

  公开号：US20100004452A1

  公开（公告）日：2010-01-07

  Disclosed are compounds of formula (I) wherein R 1 is C 1-6 alkyl, halo or haloC 1-6 alkyl; R 2 is hydrogen or C 1-6 alkyl; is a single or double bond; each R 3 and R 4 , which may be the same or different, are hydrogen, C 1-6 alkyl or haloC 1-6 alkyl; wherein i) when is a double bond p and q are 1, and ii) when is a single bond, p and q are 2, and one of R 3 and one of R 4 , together with their interconnecting atoms, forms a cyclopropane ring which may be substituted by one or two halo or methyl groups, which groups may be the same or different; X is CH or N; when present each R 5 , which may be the same or different, is C 1-6 alkyl or halo; or two R 5 groups may join to form a bridge, which bridge contains one or two atoms; n is 0, 1, 2 or 3; when present each R 6 which may be the same or different, is C 1-6 alkyl or halo; and m is 0, 1, 2 or 3.

  本发明涉及式（I）的化合物，其中R1为C1-6烷基，卤素或卤素C1-6烷基；R2为氢或C1-6烷基；为单键或双键；每个R3和R4，可以相同也可以不同，为氢，C1-6烷基或卤素C1-6烷基；其中i）当为双键时，p和q为1，ii）当为单键时，p和q为2，其中R3和R4中的一个以及它们的连接原子组成一个环丙烷环，该环可以被一个或两个卤素或甲基基团取代，这些基团可以相同也可以不同；X为CH或N；当存在时，每个R5可以相同也可以不同，为C1-6烷基或卤素；或两个R5基团可以结合形成一个桥，该桥包含一个或两个原子；n为0、1、2或3；当存在时，每个R6可以相同也可以不同，为C1-6烷基或卤素；m为0、1、2或3。
• BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS
  申请人：Bertani Barbara

  公开号：US20090076274A1

  公开（公告）日：2009-03-19

  Intermediates useful in the preparation of compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein A, R1, R2, R3, , p, q, and X are as defined in the specification.

  本文披露了在制备式(I)化合物及其药学上可接受的盐中有用的中间体：其中A、R1、R2、R3、p、q和X如规范中所定义。